News | May 14, 2025
Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Investment demonstrates confidence in America’s commitment to science and innovation
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
PRX-PLUS has a unique product feature with its deep-impacting formula
Subscribe To Our Newsletter & Stay Updated
